Abbott HIV-1 protease inhibitor
Executive SummaryAbbott's A-74704 "inhibits both protease activity and acute HIV-1 infection in vitro," company scientists John Erickson and colleagues report in the Aug. 3 issue of Science. Abbott says its protease inhibitor's symmetrical shape differs from other agents under study. Since the active site of HIV protease also has a symmetrical molecular structure, "symmetrical protease inhibitors should be able to effectively 'lock' into the active site of HIV protease," Abbott says. Merck, Upjohn, and SmithKline are among other firms developing protease inhibitors.
You may also be interested in...
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.